A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins.
Alberico Luigi CatapanoMichal VrablikYuri KarpovBaptiste BerthouMegan LoyMarie Baccara-DinetPublished in: Journal of cardiovascular pharmacology and therapeutics (2022)
The results from this study suggest that R/E FDCs improve LDL-C reduction and goal achievement in people with primary hypercholesterolemia inadequately controlled with statins and at VHR/HR of CVD.